{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:50:48Z","timestamp":1787237448897,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":7627,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1157\/13079818","type":"journal-article","created":{"date-parts":[[2005,10,21]],"date-time":"2005-10-21T07:34:46Z","timestamp":1129880086000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Recomendaciones para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial"],"prefix":"10.1016","volume":"63","author":[{"given":"J.","family":"Figueras Aloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Quero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1157\/13079818_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1695-4033(01)77643-6","article-title":"Sobre recomendaciones, protocolos y gu\u00edas cl\u00ednicas","volume":"55","author":"Mart\u00edn-Ancel","year":"2001","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1695-4033(00)77360-7","article-title":"Recomendaciones para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial","volume":"52","author":"Carbonell-Estrany","year":"2000","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1695-4033(02)77812-0","article-title":"Recomendaciones para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial: Revisi\u00f3n","volume":"56","author":"Carbonell-Estrany","year":"2002","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib4","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1542\/peds.112.6.1442","article-title":"Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections","volume":"112","year":"2003","journal-title":"Pediatrics"},{"key":"10.1157\/13079818_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1157\/13079818_bib6","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/S0264-410X(03)00352-9","article-title":"Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women","volume":"21","author":"Mu\u00f1oz","year":"2003","journal-title":"Vaccine"},{"issue":"Suppl I, Part 2","key":"10.1157\/13079818_bib7","first-page":"352.","article-title":"Respiratory Syncytial virus epidemiology in Belgium in 1998, 1999 y 2000","volume":"29","author":"Ducoffre","year":"2001","journal-title":"J Perinat Med"},{"key":"10.1157\/13079818_bib8","series-title":"Field\u2019s virology","first-page":"1313","article-title":"Respiratory syncytial virus","author":"Collins","year":"1996"},{"key":"10.1157\/13079818_bib9","series-title":"Pediatric respiratory disease: Diagnosis and treatment","first-page":"205","article-title":"Bronchiolitis","author":"Black-Payne","year":"1993"},{"key":"10.1157\/13079818_bib10","doi-asserted-by":"crossref","unstructured":"Editorial. Respiratory syncytial virus: A community problem. BMJ. 1979;2:457-8.","DOI":"10.1136\/bmj.2.6188.457"},{"key":"10.1157\/13079818_bib11","series-title":"En: New Vaccine Development Establishing Priorities","year":"1988"},{"key":"10.1157\/13079818_bib12","first-page":"143","article-title":"Bronquiolitis. Revisi\u00f3n de 153 casos y estudio comparative del tratamiento con ribavirina","volume":"46","author":"Colinas","year":"1997","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1017\/S0950268803008926","article-title":"Hospitalization for respiratory syncytial virus in the paediatric population in Spain","volume":"131","author":"Vicente","year":"2003","journal-title":"Epidemiol Infect"},{"key":"10.1157\/13079818_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1695-4033(01)77644-8","article-title":"Infecciones virales de v\u00edas respiratorias inferiores en lactantes hospitalizados: etiolog\u00eda, caracter\u00edsticas cl\u00ednicas y factores de riesgo","volume":"55","author":"Garc\u00eda-Garc\u00eda","year":"2001","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","article-title":"Respiratory sycytial virus infection","volume":"354","author":"Simoes","year":"1999","journal-title":"Lancet"},{"key":"10.1157\/13079818_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3928\/0090-4481-20050101-10","article-title":"Advances in the treatment and prevention of severe viral bronchiolitis","volume":"34","author":"Domachowske","year":"2005","journal-title":"Pediatric Annals"},{"key":"10.1157\/13079818_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/adc.2003.029710","article-title":"Hospital admission of high risk infants for respiratory syncytial virus infection: Implications for palivizumab prophylaxis","volume":"90","author":"Heikkinen","year":"2005","journal-title":"Arch Dis Child Fetal Neonatal"},{"key":"10.1157\/13079818_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1651-2227.2003.tb00533.x","article-title":"Rehospitalization for respiratory syncytial virus infection in infants with extremely low gestational age or birthweight in Denmark","volume":"92","author":"Pedersen","year":"2003","journal-title":"Acta Paediatr"},{"key":"10.1157\/13079818_bib19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/01.inf.0000086403.50417.7c","article-title":"Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants","volume":"22","author":"Pedraz","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ppul.10047","article-title":"Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections,and association between respiratory syncytial virus infectionrisk factors and disease severity","volume":"33","author":"Lanari","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1157\/13079818_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00006454-200007000-00002","article-title":"Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study","volume":"19","author":"Carbonell-Estrany","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00006454-200109000-00010","article-title":"Hospitalization rates for respiratory syncytial virus infection in premature infants younger born during two consecutive seasons","volume":"20","author":"Carbonell-Estrany","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib23","first-page":"537","article-title":"Comparaci\u00f3n con el Impact-RSV Study Group","volume":"53","author":"Bonillo","year":"2000","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib24","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/00006454-200011000-00007","article-title":"Effectiveness of palivizumab; evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season","volume":"19","author":"Sorrentino","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/322043","article-title":"Phase I evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants","volume":"184","author":"Boeckh","year":"2001","journal-title":"JID"},{"key":"10.1157\/13079818_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.inf.0000053884.21238.13","article-title":"Selected populations at increased risk from respiratory syncytial virus infection","volume":"22","author":"Cody Meissner","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ppul.10099","article-title":"Prediction of duration of hospitalization in respiratory syncytial virus infection","volume":"33","author":"Kneyber","year":"2002","journal-title":"Pediatric Pulmonol"},{"key":"10.1157\/13079818_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/adc.85.6.463","article-title":"Health Care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection","volume":"85","author":"Greenhough","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1157\/13079818_bib29","first-page":"1","article-title":"Aggiornamento 2004","volume":"1","year":"2004","journal-title":"Acta Neonatologica"},{"key":"10.1157\/13079818_bib30","unstructured":"National Advisory Committee on Immunization (NACI). Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab). CCDR. 2003;29(ACS-7,8):1-16."},{"key":"10.1157\/13079818_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1067\/S0022-3476(03)00509-2","article-title":"Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes","volume":"143","author":"Horn","year":"2003","journal-title":"J Pediatr"},{"key":"10.1157\/13079818_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/S0022-3476(03)00513-4","article-title":"Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants","volume":"143","author":"Sampalis","year":"2003","journal-title":"J Pediatr"},{"key":"10.1157\/13079818_bib33","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1542\/peds.2004-0959","article-title":"Analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program","volume":"114","author":"Wegner","year":"2004","journal-title":"Pediatrics"},{"key":"10.1157\/13079818_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1067\/S0022-3476(03)00511-0","article-title":"Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease","volume":"143","author":"Simoes","year":"2003","journal-title":"J Pediatr"},{"key":"10.1157\/13079818_bib35","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1542\/peds.2004-0059","article-title":"Severity of respiratory syncytial virus bronchiolitis is affected by cigarrete smoke exposure and atopy","volume":"115","author":"Bradley","year":"2005","journal-title":"pediatrics"},{"key":"10.1157\/13079818_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1067\/S0022-3476(03)00508-0","article-title":"Review of epidemiology and clinical risk factors for severe respiratory syncytial virus infection","volume":"143","author":"Welliver","year":"2003","journal-title":"J Pediatr"},{"key":"10.1157\/13079818_bib37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/01.inf.0000136869.21397.6b","article-title":"Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain","volume":"23","author":"Figueras-Aloy","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.inf.0000137568.71589.bd","article-title":"The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 through 35 Completed Weeks of Gestation","volume":"23","author":"Law","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ppul.10288","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001:Results from the palivizumab outcomes registry","volume":"35","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"10.1157\/13079818_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.inf.0000053885.34703.84","article-title":"Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: Results from four years of palivizumab usage","volume":"22","author":"Romero","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib41","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00006454-200206000-00007","article-title":"Palivizumab prophylaxis for respiratory syncytial virus in Canada: Utilization and outcomes","volume":"21","author":"Oh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl","key":"10.1157\/13079818_bib42","first-page":"24","article-title":"Experience with palivizumab prophylaxis for preventing RSV disease","volume":"2","author":"Cohen","year":"2000","journal-title":"J Resp Dis Pediatr"},{"key":"10.1157\/13079818_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","article-title":"Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years","volume":"354","author":"Stein","year":"1999","journal-title":"Lancet"},{"key":"10.1157\/13079818_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.200406-730OC","article-title":"Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13","volume":"171","author":"Sigurs","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13079818_bib45","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1164\/ajrccm.161.5.9906076","article-title":"Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7","volume":"161","author":"Sigurs","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl B","key":"10.1157\/13079818_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0954-6111(02)90067-3","article-title":"The association between respiratory syncytial virus infection and reactive airway disease","volume":"96","author":"Piedimonte","year":"2002","journal-title":"Respiratory Medicine"},{"key":"10.1157\/13079818_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.inf.0000053889.39392.a7","article-title":"Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma","volume":"22","author":"Martinez","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib48","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1128\/AAC.48.5.1811-1822.2004","article-title":"Anti-respiratory syncytial virus (RSV) neutralizing antibody decrease lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model","volume":"48","author":"Mej\u00edas","year":"2004","journal-title":"Antimicrob Ag Chemother"},{"key":"10.1157\/13079818_bib49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1164\/rccm.200308-1203OC","article-title":"Latency and persistence of respiratory syncytial virus despite T cell immunity","volume":"169","author":"Schwarze","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13079818_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1695-4033(04)78805-0","article-title":"Asma y virus respiratorio sincitial. Nuevas oportunidades de intervenci\u00f3n terap\u00e9utica","volume":"61","author":"Mej\u00edas","year":"2004","journal-title":"An Pediatr (Barc)"},{"key":"10.1157\/13079818_bib51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1695-4033(02)77905-8","article-title":"Asma y virus respiratorio sincitial \u00bfMito o realidad?","volume":"57","author":"Mej\u00edas","year":"2002","journal-title":"An Esp Pediatr"},{"key":"10.1157\/13079818_bib52","series-title":"14th European Respiratory Society Annual Congress","article-title":"Palivizumab use decrease risk of recurrent wheezing in preterm children","author":"Simoes","year":"2004"},{"key":"10.1157\/13079818_bib53","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archpedi.156.12.1251","article-title":"Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid\u2019s-high-risk children","volume":"156","author":"Shireman","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1157\/13079818_bib54","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/archpedi.156.10.1034","article-title":"Economic analyses of respiratory syncytial virus immunoprphylaxis in high-risk infants","volume":"156","author":"Kamal-Bahl","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1157\/13079818_bib55","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archpedi.156.12.1180","article-title":"Shedding light or creating confusion?","volume":"156","author":"Klassen","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1157\/13079818_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00431-002-1106-6","article-title":"Economic evaluation of possible prevention of RSV-related hospitalisations in premature infants in Germany","volume":"162","author":"Roeckl-Wedmann","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1157\/13079818_bib57","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1542\/peds.2004-1107","article-title":"Hand Hygiene Practices in a Neonatal Intensive Care Unit: A Multimodal Intervention and Impact on Nosocomial Infection","volume":"114","author":"Lam","year":"2004","journal-title":"Pediatrics"},{"key":"10.1157\/13079818_bib58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"10.1157\/13079818_bib59","unstructured":"Su\u00e1rez P, Malo P, Maroto E, Santos de Soto J. Recomendaciones para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial en pacientes con cardiopat\u00eda cong\u00e9nita. Disponible en: http:\/\/www.secardioped.org\/pdfs\/profilaxis_virus-vrs.htm"},{"key":"10.1157\/13079818_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.inf.0000144664.31888.53","article-title":"Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation","volume":"23","author":"Carbonell-Estrany","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1440-1754.2002.00790.x","article-title":"Cost-effectiveness of palivizumab in New Zealand","volume":"38","author":"Vogel","year":"2002","journal-title":"J Pediatr Child Health"},{"key":"10.1157\/13079818_bib62","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.inf.0000145406.74341.c7","article-title":"Severe respiratory syncytial virus bronchiolitis: Epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia","volume":"23","author":"Grimaldi","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib63","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.inf.0000133165.85909.08","article-title":"Safety and pharmacokinetics of palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection","volume":"23","author":"Saez-Llorens","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib64","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1542\/peds.2004-0226","article-title":"Palivizumab use in very premature infants in the neonatal intensive care unit","volume":"114","author":"Wu","year":"2004","journal-title":"Pediatrics"},{"key":"10.1157\/13079818_bib65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00006454-200404000-00013","article-title":"Deaths among children less than two years of age receiving palivizumab:An analysis of comorbidities","volume":"23","author":"Mohan","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1157\/13079818_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00148581-200406030-00004","article-title":"Palivizumab: A review of its use as prophylaxis for serious respiratory syncytial virus infection","volume":"6","author":"Fenton","year":"2004","journal-title":"Pediatr Drugs"},{"key":"10.1157\/13079818_bib68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00002018-200326040-00005","article-title":"Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection","volume":"26","author":"Lacaze-Masmonteil","year":"2003","journal-title":"Drug Safety"},{"key":"10.1157\/13079818_bib69","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1542\/peds.110.5.e53","article-title":"Reported adverse drug events in infants and children under 2 years of age","volume":"110","author":"Moore","year":"2002","journal-title":"Pediatrics"},{"key":"10.1157\/13079818_bib70","unstructured":"Agencia Espa\u00f1ola del Medicamento. Comunicado sobre riesgos de medicamentos para profesionales sanitarios: Nota Informativa sobre la seguridad de palivizumab. Ref: 2002\/11,2 de Diciembre de 2002. Disponible en: http:\/\/www.msc.es\/agemed\/csmh\/notas\/palivizumab.asp"}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S169540330570206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S169540330570206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:15:17Z","timestamp":1787105717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S169540330570206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S169540330570206X"],"URL":"https:\/\/doi.org\/10.1157\/13079818","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones para la prevenci\u00f3n de la infecci\u00f3n por virus respiratorio sincitial","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1157\/13079818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}